Pfizer (PFE)

Sales/Maturities of Investments

$2.13B

Quarterly · Period ending: · USD

PFE logo

PFE Sales/Maturities of Investments

Latest reported$2.13B
PFE Quarterly Sales/Maturities of Investments ($200.10M → $2.13B)
High-resolution chart · PNG

PFE sales/maturities of investments history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Pfizer Sales/Maturities of Investments — Quarterly (USD)
Period endingSales/Maturities of Investments (USD)
2,127,000,000
4,664,000,000
2,639,000,000
3,095,000,000
12,919,000,000
4,037,000,000
2,014,000,000
1,258,000,000
4,599,000,000
963,000,000
34,312,000,000
10,556,000,000
-9,640,000,000
11,189,000,000
9,929,000,000
15,156,000,000
6,904,000,000
16,882,000,000
11,675,000,000
8,552,000,000
2,148,000,000
5,721,000,000
3,685,000,000
3,914,000,000
1,722,000,000
3,409,000,000
151,000,000
5,329,000,000
1,274,000,000
9,586,000,000
4,597,000,000
2,222,000,000
1,543,000,000
11,546,000,000
5,001,000,000
2,475,000,000
1,624,000,000
6,859,000,000
6,605,000,000
16,901,000,000
7,627,000,000
9,557,000,000
9,060,000,000
16,907,000,000
8,912,000,000
17,882,000,000
14,984,000,000
17,324,000,000
14,618,000,000
10,523,000,000
13,731,000,000
17,255,000,000
9,866,000,000
7,830,000,000
9,017,000,000
9,072,000,000
4,618,000,000
9,044,000,000
7,738,000,000
5,050,000,000
5,115,000,000
9,294,000,000
1,559,000,000
-889,000,000
1,689,000,000
12,515,000,000
18,072,000,000
18,836,000,000
10,135,000,000
7,600,000,000
15,524,000,000
8,186,000,000
6,236,000,000
6,859,000,000
6,861,000,000
6,476,000,000
5,299,000,000
11,824,000,000
3,429,000,000
4,289,000,000
2,844,000,000
10,442,000,000
4,254,000,000
10,696,000,000
10,151,000,000
2,987,000,000
5,434,000,000
3,188,000,000
1,242,000,000
3,429,000,000
2,036,000,000
3,575,000,000
3,896,000,000
2,909,000,000
1,227,000,000
5,543,000,000
2,647,000,000
3,841,000,000
4,940,000,000
4,420,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.